So long to Sola; Lilly bloom’s hope withers big pharma continues to ‘Chase’ AD dream

28
Nov

By Randy Osborne

Last week’s phase III blowup of Eli Lilly and Co.’s solanezumab(sola) in Alzheimer’s disease (AD) struck up a familiar dirge in the failure-strewn space, and set experts to debating – again, still – the amyloid beta hypothesis, as companies that have chosen to pursue other routes continued to laud their approaches and ever-ambitious big pharma snatched up another player in the space.

Read full article here: http://www.bioworld.com/content/so-long-sola-lilly-bloom%E2%80%99s-hope-withers-big-pharma-continues-%E2%80%98chase%E2%80%99-ad-dream-0

X